The FDA's "abstinence" outcome measure for approval of new medications to treat opioid-use disorders has been difficult to achieve; developing and validating alternative meaningful outcomes could facilitate drug development.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1126/scitranslmed.aan2595 | DOI Listing |
Publication Analysis
Top Keywords
medication development
4
development opioid
4
opioid addiction
4
addiction meaningful
4
meaningful clinical
4
clinical points
4
points fda's
4
fda's "abstinence"
4
"abstinence" outcome
4
outcome measure
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!